BioCentury | Oct 13, 2014
Clinical News

18-methoxycoronaridine: Phase I started

Savant said partner Hebron Farmaceutica began a double-blind, placebo-controlled, Brazilian Phase I trial to evaluate oral 18-MC in healthy volunteers. Hebron is developing the compound outside of North America for leishmaniasis under an expanded material...
BioCentury | Jan 14, 2013
Company News

Savant HWP, National Institutes of Health neurology, endocrine/metabolic news

Savant HWP received a $6.5 million grant from the NIH's National Institute on Drug Abuse (NIDA) to develop Savant's 18-methoxycoronaridine (18-MC) to treat drug addiction, obesity and other forms of compulsive behavior. 18-MC is a...
BioCentury | Dec 24, 2012
Emerging Company Profile

Savant HWP: Antagonizing addiction

Savant HWP Inc. has developed selective antagonists of the nicotinic acetylcholine receptor alpha(3)beta(4) it believes could treat a wide variety of addiction disorders because the compounds hit a pathway that underlies most pleasure-seeking behaviors, including...
Items per page:
1 - 3 of 3